Physician profile
Samuel D Morris
NPI 1427092956
$6,436.15
in general payments reported to CMS, 2019-2025
37 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $609 · 2021: $778 · 2022: $816 · 2023: $1,198 · 2024: $668 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,158.43 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $567.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $548.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $538.44 | 2019-2025 | |
| Astellas Pharma US INC | $371.72 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $365.89 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $310.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $287.26 | 2019-2024 | Xarelto |
| Abbott Laboratories | $255.07 | 2021-2022 | |
| Allergan, INC. | $252.77 | 2019-2020 | |
| Amgen INC. | $207.50 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $160.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $135.75 | 2021-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $129.83 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $111.86 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.